Decoy Therapeutics (DCOY) CFO Mark Rosenblum Receives Restricted Stock Award

What Happened Mark J. Rosenblum, Chief Financial Officer of Decoy Therapeutics (DCOY), was granted 9,682 restricted shares on August 31, 2026. The filing reports an acquisition price of $0.00 (a compensatory grant/award), so no cash was exchanged. The grant is recorded as an award under the company’s 2026 Equity Incentive Plan.

Key Details

• Transaction date: 2026-08-31 (Grant/Award, code A)
• Shares granted: 9,682; reported acquisition price: $0.00
• Vesting: 25% vested immediately; remaining shares vest in approximately equal monthly increments over the next 36 months (see footnote F1)
• Shares beneficially owned following the transaction were adjusted to reflect reverse stock splits effective Aug 15, 2025 and Mar 6, 2026 (footnote F2); the filing does not list a post-transaction total beneficial ownership in the provided summary
• No 10b5-1, tax-withholding sale, or late-filing indication included in the filing

Context This is a compensatory restricted stock award (not an open-market purchase or sale). Grants like this are common for executive compensation and align incentives with shareholders through vesting; they do not by themselves indicate personal buying or selling intent. Retail investors should note the vesting schedule to understand when shares may become freely tradable.